Technology and Information Transfer. On a Product-by-Product basis, within [***] ([***]) calendar days after Akcea grants Novartis the license for such Product under Section 5.1, Akcea will deliver to Novartis the following Licensed Know-How pursuant to a technology transfer plan to be mutually agreed by Akcea and Novartis:
Technology and Information Transfer. Commencing promptly after the Effective Date and from time to time thereafter during the Term, Replidyne shall disclose to Forest such Licensed Technology in Replidyne’s possession as is reasonably necessary or useful to enable Forest to exercise fully the licenses granted to Forest under Article 2. Commencing promptly after the Effective Date and from time to time thereafter during the Term, Forest will disclose to Replidyne such Forest Technology in Forest’s possession as is reasonably necessary or useful to enable Replidyne to perform its Development Program activities hereunder in accordance with the Development Plan and otherwise to exercise fully the licenses granted to Replidyne under Article 2 hereof. Each party will, at no cost or expense to the other party, provide such other party with copies of or access to any and all Development Information generated or otherwise obtained in the development of Products as provided in this Section 4.3, all of which Development Information may be used and referenced by or on behalf of Forest in the development, manufacture and/or commercialization of Product in the Field in the Territory in accordance with the terms of this Agreement and by or on behalf of Replidyne in the performance by Replidyne of the development and commercialization activities with respect to the Product in the Field in the Territory in accordance with the terms of this Agreement and (including, as appropriate and, without limitation, by DAP) in the development, manufacture and/or commercialization of Product in the Field outside the Territory, including, without limitation, in the preparation, submission, filing, prosecution and maintenance of regulatory approvals in the applicable territory. Moreover, upon reasonable written notice from a party, the other party will provide regulatory authorities with access to any Development Information for inspection and/or review as may be required under Applicable Law.
Technology and Information Transfer. CoCensys will provide to Wyeth-Ayerst all Know-How as Wyeth-Ayerst deems necessary to carry out the Development and [ * ] of the Product and to obtain Regulatory Approval. All information transferred, provided or exchanged under this Article 2.2.1 will be subject to the confidentiality requirements set forth in Article 17.
Technology and Information Transfer. GalaGen will provide to Wyeth-Ayerst all GalaGen Know-How as Wyeth-Ayerst deems necessary to carry out its responsibilities in the Collaboration and to manufacture and obtain Regulatory Approval for Products. Wyeth-Ayerst will provide to GalaGen all Wyeth-Ayerst Know-How as Wyeth-Ayerst deems necessary for GalaGen to carry out its responsibilities in the Collaboration. All information transferred, provided or exchanged under this Section 2.4.1 will be subject to the confidentiality requirements set forth in Article 12 hereof.
Technology and Information Transfer. Isis will (i) promptly, but no later than [***] days following the date (y) Bayer pays Isis the milestone payment for [***], in the case of the Licensed Know-How licensed to Bayer under Section 5.1.1, or (z) on a New Drug Option Program-by-New Drug Option Program basis, the license under Section 5.1.2 or Section 5.1.3 (as applicable) is granted to Bayer with respect to the Development Candidate for such New Drug Option Program, and (ii) during the Agreement Term promptly following Bayer’s reasonable request deliver to Bayer the following Licensed Know-How:
5.4.1. Licensed Know-How - Generally. Copies of Licensed Know-How (other than the Isis Manufacturing and Analytical Know-How) in the Field in Isis’ possession that has not previously been provided hereunder, for use solely in accordance with the licenses granted under Section 5.1.1, Section 5.1.2 or Section 5.1.3, as the case may be, to Bayer, which includes, for ISIS-FXIRx, (i) the information included in the IND, and (ii) the data from the Phase 1 Clinical Trials and Phase 2 Clinical Trials conducted by Isis, together with all regulatory documentation.
5.4.2. Isis Manufacturing and Analytical Know-How. Solely for use by Bayer, its Affiliates or a Third Party acting on Bayer’s behalf to Manufacture API in Bayer’s own [***] manufacturing facility, copies of the Isis Manufacturing and Analytical Know-How relating to Products in Isis’ possession that has not previously been provided hereunder, which is necessary for the exercise by Bayer, [***] of the Manufacturing rights granted under Section 5.1.1, Section 5.1.2 or Section 5.1.3, as the case may be.
Technology and Information Transfer. Isis will (i) promptly, but no later than [***] days following the date (y) Bayer pays Isis the milestone payment for [***], in the case of the Licensed Know-How licensed to Bayer under Section 5.1.1, or (z) on a New Drug Option Program-by-New Drug Option Program basis, the license under Section 5.1.2 or Section 5.1.3 (as applicable) is granted to Bayer with respect to the Development Candidate for such New Drug Option Program, and (ii) during the Agreement Term promptly following Bayer’s reasonable request deliver to Bayer the following Licensed Know-How:
Technology and Information Transfer. Neose agrees to supply Wyeth-Ayerst with all Neose Technology required by Wyeth-Ayerst to carry out its activities under the Research Program and to manufacture, package, and obtain Regulatory Approval for Products. Wyeth-Ayerst agrees to supply Neose with all Wyeth-Ayerst Know-How necessary for Neose to carry out its activities under the Research Program. All information transferred, provided or exchanged under this Section 2.2 shall be subject to the confidentiality provisions of Section 12 hereof.
Technology and Information Transfer. On a Product-by-Product basis, within [***] ([***]) calendar days after Akcea grants Novartis the license for such Product under Section 5.1, Akcea will deliver to Novartis the following Licensed Know-How pursuant to a technology transfer plan to be mutually agreed by Xxxxx and Novartis:
5.7.1. Licensed Know-How - Generally. Copies of Licensed Know-How (other than the Akcea Manufacturing and Analytical Know-How) in Xxxxx’s possession that has not previously been provided hereunder, for use solely in accordance with the licenses granted under Section 5.1.1 or Section 5.1.2, as the case may be, to Novartis, which includes transferring to Novartis the applicable IND and delivering copies of information included in such IND and the data from the Phase 1 Trials and Phase 2 Trials conducted by Akcea, together with all regulatory documentation.
5.7.2. Akcea Manufacturing and Analytical Know-How. Solely for use by Novartis, its Affiliates or a Third Party as permitted under Section 5.2, copies of the Akcea Manufacturing and Analytical Know-How relating to Products in Akcea’s possession that has not previously been provided hereunder, which is necessary for Novartis, its Affiliates or a Third Party to exercise the Manufacturing rights granted under Section 5.1.1 or Section 5.1.2, as the case may be.
Technology and Information Transfer. Licensee shall provide to Licensor all technical information and know how relating to the Technology or any Valuable Product discovered by Licensee and shall provide all technical assistance, engineering reports, modifications, upgrades and training to Licensor, as shall be necessary to carry out the development and commercialization of the Technology or any Valuable Product created therefrom and as necessary to obtain any required governmental and regulatory approvals for the Technology or any Valuable Product created therefrom in the jurisdictions where the Technology or any Valuable Product created therefrom is/are to be marketed and/or sold. All information transferred, provided, or exchanged under this Section 4.3 shall be subject to the confidentiality requirements set forth in Section 6 and may be used only in accordance with this Agreement.
Technology and Information Transfer. Following the Effective Date, Coulxxx xxxl promptly provide to SB all KNOW-HOW and other information, including, but not limited to, preclinical and clinical data, as SB reasonably deems necessary to enable it to carry out the DEVELOPMENT and MANUFACTURE DEVELOPMENT of LICENSED COMPOUND and PRODUCT and commercialization of PRODUCT and to obtain REGULATORY APPROVAL throughout the TERRITORY. Thereafter, during the term of this Agreement, each Party shall promptly make available to the other all KNOW-HOW and other information, including, but not limited to, preclinical and clinical data, as such Party reasonably deems necessary to carry out the DEVELOPMENT and MANUFACTURE DEVELOPMENT of LICENSED COMPOUND and PRODUCT and commercialization of PRODUCT and to obtain REGULATORY APPROVAL throughout the TERRITORY. All information transferred, provided or exchanged under this Section 3.4.1 will be subject to the confidentiality requirements set forth in Article 17.
